Search

everythinglearnresearchcommunity

for

Search:↓

A new compound slows cancer cell growth and causes cell death by blocking cell cycle progression and increasing cell-damaging molecules.

Oncogenic K-ras causes rapid cancerous changes in the mouth's lining.

Using protein degradation to fight cancer drug resistance shows promise but needs more precise targeting and fewer side effects.

Paclitaxel is an effective cancer drug with side effects and potential new uses beyond cancer.

Nanocarrier-loaded gels improve drug delivery for cancer, skin conditions, and hair loss.

TGM3 is important for skin and hair structure and may help diagnose cancer.

EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.

New drugs targeting DNA enzymes show promise for cancer treatment but have side effects like immune system suppression and hair loss.

Key genes linked to hair growth and cancer were identified in hairless mice.

Keratin 18 helps diagnose and predict cancer progression and affects cancer growth and spread.

Blocking the Wnt pathway could lead to new treatments for cancer and tissue repair but requires careful development to avoid side effects.

Some plants used in traditional medicine may help treat cancer because they contain proteins that can inactivate ribosomes.

The document provides advice on how to recognize and treat skin-related side effects of cancer drugs known as EGFR inhibitors.

New treatments targeting the Hedgehog pathway can help treat advanced skin cancer but may have side effects and their effectiveness in early stages is unknown.

Plant-derived extracellular vesicles show promise for treating diseases like cancer and inflammation.

A specific hair protein variant increases the spread of breast cancer and is linked to worse survival rates.

Docetaxel is safe and works well for older people with cancer, with manageable side effects.

The PDGF/PDGFR pathway is a potential drug target with mixed success in treating various diseases, including some cancers and fibrosis.

New patents show progress in developing drugs targeting the Wnt pathway for diseases like cancer and hair loss.

The article concludes that while we understand a lot about how melanocytes age and how this can prevent cancer, there are still unanswered questions about certain pathways and genes involved.

Using a combination of specific cell cycle regulators is better for safely keeping hair root cells alive indefinitely compared to cancer-related methods.

Metformin, a diabetes drug, may also help fight cancer, but more research is needed to understand how.

The document highlights various patents for new compounds with potential treatments for multiple diseases, including cancer, hormonal disorders, and diabetes.

The Rotterdam Study updated its design and objectives in 2012, providing insights into various diseases in the elderly, including skin cancer, bone health, liver disease, neurological and psychiatric conditions, and respiratory issues.

Fibroblast growth factor receptor signaling controls cell development and repair, and its malfunction can cause disorders and cancer, but it also offers potential for targeted therapies.

The FDA warned about safety issues with remdesivir and tofacitinib, finasteride is linked to suicidality, potent topical corticosteroids increase osteoporosis risk, henna can cause hemolysis in G6PD deficiency, chemotherapeutic agents can cause adverse reactions, drug interactions are common in cancer patients, ketamine can reduce at-risk drinking, high dose of anticholinergics increases dementia risk in Parkinson's patients, and prenatal exposure to second-generation antipsychotics increases pregnancy complications.

Overexpression of HDGF in melanocytes does not cause cancer.

Targeting the skin's endocannabinoid system could help treat skin disorders.

Breast cancer treatments work better with AR activation, improving results and reducing side effects.

KRT80 may worsen cancer by increasing growth and spread, but its full effects on treatment and outcomes need more research.